Skip to main content
SpringerLink
Log in

Transcriptome modeling and phenotypic assays for cancer precision medicine

  • Review
  • Published:
Archives of Pharmacal Research Aims and scope Submit manuscript

Abstract

Cancer precision medicine requires clinically actionable biomarkers for patient stratification and a better prediction of clinical outcome. Although thousands of cancer-enriched mutated genes have been reported by global sequencing projects, to date, only a few oncogenic mutations have been confirmed as effective biomarkers in cancer therapies. The low frequency and varied profile (i.e., allele frequency, mutation position) of mutant genes among cancer types limit the utility of predictive biomarkers. The recent explosion of cancer transcriptome and phenotypic screening data provides another opportunity for finding transcript-level biomarkers and targets, thus overcoming the limitation of cancer mutation analyses. Technological developments enable the rapid and extensive discovery of potential target-biomarker combinations from large-scale transcriptome-level screening combined with physiologically relevant phenotypic assays. Here, we summarized recent progress as well as discussed the outlook of transcriptome-oriented data mining strategies and phenotypic assays for the identification of non-genetic biomarkers and targets in cancer drug discovery.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  • Abaan OD, Polley EC, Davis SR, Zhu YJ, Bilke S, Walker RL, Pineda M, Gindin Y, Jiang Y, Reinhold WC, Holbeck SL, Simon RM, Doroshow JH, Pommier Y, Meltzer PS (2013) The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology. Cancer Res 73:4372–4382

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Aguirre AJ, Meyers RM, Weir BA, Vazquez F, Zhang CZ, Ben-David U, Cook A, Ha G, Harrington WF, Doshi MB, Kost-Alimova M, Gill S, Xu H, Ali LD, Jiang G, Pantel S, Lee Y, Goodale A, Cherniack AD, Oh C, Kryukov G, Cowley GS, Garraway LA, Stegmaier K, Roberts CW, Golub TR, Meyerson M, Root DE, Tsherniak A, Hahn WC (2016) Genomic copy number dictates a gene-independent cell response to CRISPR/Cas9 targeting. Cancer Discov 6:914–929

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Aken BL, Ayling S, Barrell D, Clarke L, Curwen V, Fairley S, Fernandez Banet J, Billis K, Garcia Giron C, Hourlier T, Howe K, Kahari A, Kokocinski F, Martin FJ, Murphy DN, Nag R, Ruffier M, Schuster M, Tang YA, Vogel JH, White S, Zadissa A, Flicek P, Searle SM (2016) The Ensembl gene annotation system. Database. doi:10.1093/database/baw093

    PubMed  PubMed Central  Google Scholar 

  • Arai K, Eguchi T, Rahman MM, Sakamoto R, Masuda N, Nakatsura T, Calderwood SK, Kozaki K, Itoh M (2016) A novel high-throughput 3D screening system for EMT inhibitors: a pilot screening discovered the EMT inhibitory activity of CDK2 inhibitor SU9516. PLoS ONE 11:e0162394

    Article  PubMed  PubMed Central  Google Scholar 

  • Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehar J, Kryukov GV, Sonkin D, Reddy A, Liu M, Murray L, Berger MF, Monahan JE, Morais P, Meltzer J, Korejwa A, Jane-Valbuena J, Mapa FA, Thibault J, Bric-Furlong E, Raman P, Shipway A, Engels IH, Cheng J, Yu GK, Yu J, Aspesi P Jr, De Silva M, Jagtap K, Jones MD, Wang L, Hatton C, Palescandolo E, Gupta S, Mahan S, Sougnez C, Onofrio RC, Liefeld T, Macconaill L, Winckler W, Reich M, Li N, Mesirov JP, Gabriel SB, Getz G, Ardlie K, Chan V, Myer VE, Weber BL, Porter J, Warmuth M, Finan P, Harris JL, Meyerson M, Golub TR, Morrissey MP, Sellers WR, Schlegel R, Garraway LA (2012) The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483:603–607

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bray MA, Singh S, Han H, Davis CT, Borgeson B, Hartland C, Kost-Alimova M, Gustafsdottir SM, Gibson CC, Carpenter AE (2016) Cell painting, a high-content image-based assay for morphological profiling using multiplexed fluorescent dyes. Nat Protoc 11:1757–1774

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Caicedo JC, Singh S, Carpenter AE (2016) Applications in image-based profiling of perturbations. Curr Opin Biotechnol 39:134–142

    Article  CAS  PubMed  Google Scholar 

  • Cowley GS, Weir BA, Vazquez F, Tamayo P, Scott JA, Rusin S, East-Seletsky A, Ali LD, Gerath WF, Pantel SE, Lizotte PH, Jiang G, Hsiao J, Tsherniak A, Dwinell E, Aoyama S, Okamoto M, Harrington W, Gelfand E, Green TM, Tomko MJ, Gopal S, Wong TC, Li H, Howell S, Stransky N, Liefeld T, Jang D, Bistline J, Hill Meyers B, Armstrong SA, Anderson KC, Stegmaier K, Reich M, Pellman D, Boehm JS, Mesirov JP, Golub TR, Root DE, Hahn WC (2014) Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies. Sci Data 1:140035

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Deeken JF, Robey RW, Shukla S, Steadman K, Chakraborty AR, Poonkuzhali B, Schuetz EG, Holbeck S, Ambudkar SV, Bates SE (2009) Identification of compounds that correlate with ABCG2 transporter function in the National Cancer Institute Anticancer Drug Screen. Mol Pharmacol 76:946–956

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Domcke S, Sinha R, Levine DA, Sander C, Schultz N (2013) Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun 4:2126

    Article  PubMed  PubMed Central  Google Scholar 

  • Erb MA, Scott TG, Li BE, Xie H, Paulk J, Seo HS, Souza A, Roberts JM, Dastjerdi S, Buckley DL, Sanjana NE, Shalem O, Nabet B, Zeid R, Offei-Addo NK, Dhe-Paganon S, Zhang F, Orkin SH, Winter GE, Bradner JE (2017) Transcription control by the ENL YEATS domain in acute leukaemia. Nature 543:270–274

    Article  CAS  PubMed  Google Scholar 

  • Forbes SA, Beare D, Boutselakis H, Bamford S, Bindal N, Tate J, Cole CG, Ward S, Dawson E, Ponting L, Stefancsik R, Harsha B, Kok CY, Jia M, Jubb H, Sondka Z, Thompson S, De T, Campbell PJ (2017) COSMIC: somatic cancer genetics at high-resolution. Nucleic Acids Res 45:D777–D783

    Article  PubMed  Google Scholar 

  • Fu J, Fernandez D, Ferrer M, Titus SA, Buehler E, Lal-Nag MA (2017) RNAi high-throughput screening of single- and multi-cell-type tumor spheroids: a comprehensive analysis in two and three dimensions. SLAS Discov 22:525–536

    PubMed  Google Scholar 

  • Gimenez CA, Ielpi M, Mutto A, Grosembacher L, Argibay P, Pereyra-Bonnet F (2016) CRISPR-on system for the activation of the endogenous human INS gene. Gene Ther 23:543–547

    Article  CAS  PubMed  Google Scholar 

  • Gonzalez De Castro D, Clarke PA, Al-Lazikani B, Workman P (2013) Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance. Clin Pharmacol Ther 93:252–259

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gu Y, Wang R, Han Y, Zhou W, Zhao Z, Chen T, Zhang Y, Peng F, Liang H, Qi L, Zhao W, Yang D, Guo Z (2017) A landscape of synthetic viable interactions in cancer. Brief Bioinform. doi:10.1093/bib/bbw142

    Google Scholar 

  • Hannus M, Beitzinger M, Engelmann JC, Weickert MT, Spang R, Hannus S, Meister G (2014) siPools: highly complex but accurately defined siRNA pools eliminate off-target effects. Nucleic Acids Res 42:8049–8061

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hatzis C, Bedard PL, Birkbak NJ, Beck AH, Aerts HJ, Stem DF, Shi L, Clarke R, Quackenbush J, Haibe-Kains B (2014) Enhancing reproducibility in cancer drug screening: how do we move forward? Cancer Res 74:4016–4023

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hong Y, Kim N, Li C, Jeong E, Yoon S (2017) Patient sample-oriented analysis of gene expression highlights extracellular signatures in breast cancer progression. Biochem Biophys Res Commun 487:307–312

    Article  CAS  PubMed  Google Scholar 

  • Horlbeck MA, Gilbert LA, Villalta JE, Adamson B, Pak RA, Chen Y, Fields AP, Park CY, Corn JE, Kampmann M, Weissman JS (2016) Compact and highly active next-generation libraries for CRISPR-mediated gene repression and activation. Elife. doi:10.7554/eLife.19760

    Google Scholar 

  • Horman SR, Hogan C, Delos Reyes K, Lo F, Antczak C (2015) Challenges and opportunities toward enabling phenotypic screening of complex and 3D cell models. Future Med Chem 7:513–525

    Article  CAS  PubMed  Google Scholar 

  • Howes AL, Richardson RD, Finlay D, Vuori K (2014) 3-Dimensional culture systems for anti-cancer compound profiling and high-throughput screening reveal increases in EGFR inhibitor-mediated cytotoxicity compared to monolayer culture systems. PLoS ONE 9:e108283

    Article  PubMed  PubMed Central  Google Scholar 

  • Iorio F, Knijnenburg TA, Vis DJ, Bignell GR, Menden MP, Schubert M, Aben N, Goncalves E, Barthorpe S, Lightfoot H, Cokelaer T, Greninger P, Van Dyk E, Chang H, De Silva H, Heyn H, Deng X, Egan RK, Liu Q, Mironenko T, Mitropoulos X, Richardson L, Wang J, Zhang T, Moran S, Sayols S, Soleimani M, Tamborero D, Lopez-Bigas N, Ross-Macdonald P, Esteller M, Gray NS, Haber DA, Stratton MR, Benes CH, Wessels LF, Saez-Rodriguez J, Mcdermott U, Garnett MJ (2016) A landscape of pharmacogenomic interactions in cancer. Cell 166:740–754

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Jaiswal A, Peddinti G, Akimov Y, Wennerberg K, Kuznetsov S, Tang J, Aittokallio T (2017) Seed-effect modeling improves the consistency of genome-wide loss-of-function screens and identifies synthetic lethal vulnerabilities in cancer cells. Genome Med 9:51

    Article  PubMed  PubMed Central  Google Scholar 

  • Jeong E, He N, Park H, Song M, Kim N, Lee S, Yoon S (2015) MACE: mutation-oriented profiling of chemical response and gene expression in cancers. Bioinformatics 31:1508–1514

    Article  CAS  PubMed  Google Scholar 

  • Jiang G, Zhang S, Yazdanparast A, Li M, Pawar AV, Liu Y, Inavolu SM, Cheng L (2016) Comprehensive comparison of molecular portraits between cell lines and tumors in breast cancer. BMC Genomics 17(Suppl 7):525

    Article  PubMed  PubMed Central  Google Scholar 

  • Kelloff GJ, Sigman CC (2012) Cancer biomarkers: selecting the right drug for the right patient. Nat Rev Drug Discov 11:201–214

    Article  CAS  PubMed  Google Scholar 

  • Kim N, He N, Kim C, Zhang F, Lu Y, Yu Q, Stemke-Hale K, Greshock J, Wooster R, Yoon S, Mills GB (2012) Systematic analysis of genotype-specific drug responses in cancer. Int J Cancer 131:2456–2464

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kim N, Hong Y, Kwon D, Yoon S (2013) Somatic mutaome profile in human cancer tissues. Genomics Inform 11:239–244

    Article  PubMed  PubMed Central  Google Scholar 

  • Kim N, Yim HY, He N, Lee CJ, Kim JH, Choi JS, Lee HS, Kim S, Jeong E, Song M, Jeon SM, Kim WY, Mills GB, Cho YY, Yoon S (2016) Cardiac glycosides display selective efficacy for STK11 mutant lung cancer. Sci Rep 6:29721

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Klann TS, Black JB, Chellappan M, Safi A, Song L, Hilton IB, Crawford GE, Reddy TE, Gersbach CA (2017) CRISPR-Cas9 epigenome editing enables high-throughput screening for functional regulatory elements in the human genome. Nat Biotechnol 35:561–568

    Article  CAS  PubMed  Google Scholar 

  • Li J, Zhao W, Akbani R, Liu W, Ju Z, Ling S, Vellano CP, Roebuck P, Yu Q, Eterovic AK, Byers LA, Davies MA, Deng W, Gopal YN, Chen G, Von Euw EM, Slamon D, Conklin D, Heymach JV, Gazdar AF, Minna JD, Myers JN, Lu Y, Mills GB, Liang H (2017) Characterization of human cancer cell lines by reverse-phase protein arrays. Cancer Cell 31:225–239

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Liu Y, Yin X, Zhong J, Guan N, Luo Z, Min L, Yao X, Bo X, Dai L, Bai H (2017) Systematic identification and assessment of therapeutic targets for breast cancer based on genome-wide RNA interference transcriptomes. Genes (Basel). doi:10.3390/genes8030086

    Google Scholar 

  • Marhefka JN, Abbud-Antaki RA (2012) Validation of the Cancer BioChip System as a 3D siRNA screening tool for breast cancer targets. PLoS ONE 7:e46086

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Marugan C, Torres R, Lallena MJ (2015) Phenotypic screening approaches to develop aurora kinase inhibitors: drug discovery perspectives. Front Oncol 5:299

    PubMed  Google Scholar 

  • Paull KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA, Rubinstein L, Plowman J, Boyd MR (1989) Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst 81:1088–1092

    Article  CAS  PubMed  Google Scholar 

  • Pereira LP, Silva P, Duarte M, Rodrigues L, Duarte CM, Albuquerque C, Serra AT (2017) Targeting colorectal cancer proliferation, stemness and metastatic potential using brassicaceae extracts enriched in isothiocyanates: a 3D cell model-based study. Nutrients. doi:10.3390/nu9040368

    Google Scholar 

  • Perez-Pinera P, Kocak DD, Vockley CM, Adler AF, Kabadi AM, Polstein LR, Thakore PI, Glass KA, Ousterout DG, Leong KW, Guilak F, Crawford GE, Reddy TE, Gersbach CA (2013) RNA-guided gene activation by CRISPR-Cas9-based transcription factors. Nat Methods 10:973–976

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Rameseder J, Krismer K, Dayma Y, Ehrenberger T, Hwang MK, Airoldi EM, Floyd SR, Yaffe MB (2015) A multivariate computational method to analyze high-content RNAi screening data. J Biomol Screen 20:985–997

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Rana TM (2007) Illuminating the silence: understanding the structure and function of small RNAs. Nat Rev Mol Cell Biol 8:23–36

    Article  CAS  PubMed  Google Scholar 

  • Rauscher B, Heigwer F, Breinig M, Winter J, Boutros M (2017) GenomeCRISPR—a database for high-throughput CRISPR/Cas9 screens. Nucleic Acids Res 45:D679–D686

    Article  PubMed  Google Scholar 

  • Reinhold WC, Sunshine M, Liu H, Varma S, Kohn KW, Morris J, Doroshow J, Pommier Y (2012) Cell Miner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. Cancer Res 72:3499–3511

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Riba A, Emmenlauer M, Chen A, Sigoillot F, Cong F, Dehio C, Jenkins J, Zavolan M (2017) Explicit modeling of siRNA-dependent on- and off-target repression improves the interpretation of screening results. Cell Syst 4(182–193):e184

    Google Scholar 

  • Riss TL, Moravec RA, Niles AL, Duellman S, Benink HA, Worzella TJ, Minor L (2004) Cell Viability Assays. In: Sittampalam GS, Coussens NP, Brimacombe K, Grossman A, Arkin M, Auld D, Austin C, Baell J, Bejcek B, Chung TDY, Dahlin JL, Devanaryan V, Foley TL, Glicksman M, Hall MD, Hass JV, Inglese J, Iversen PW, Lal-Nag M, Li Z, Mcgee J, Mcmanus O, Riss T, Trask OJ Jr, Weidner JR, Xia M, Xu X (eds) Assay guidance manual. Eli Lilly & Company and the National Center for Advancing Translational Sciences, Bethesda

    Google Scholar 

  • Root DE, Hacohen N, Hahn WC, Lander ES, Sabatini DM (2006) Genome-scale loss-of-function screening with a lentiviral RNAi library. Nat Methods 3:715–719

    Article  CAS  PubMed  Google Scholar 

  • Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P, Iyer V, Jeffrey SS, Van De Rijn M, Waltham M, Pergamenschikov A, Lee JC, Lashkari D, Shalon D, Myers TG, Weinstein JN, Botstein D, Brown PO (2000) Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 24:227–235

    Article  CAS  PubMed  Google Scholar 

  • Rotem A, Janzer A, Izar B, Ji Z, Doench JG, Garraway LA, Struhl K (2015) Alternative to the soft-agar assay that permits high-throughput drug and genetic screens for cellular transformation. Proc Natl Acad Sci USA 112:5708–5713

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Roychowdhury S, Chinnaiyan AM (2016) Translating cancer genomes and transcriptomes for precision oncology. CA Cancer J Clin 66:75–88

    Article  PubMed  Google Scholar 

  • Shalem O, Sanjana NE, Zhang F (2015) High-throughput functional genomics using CRISPR-Cas9. Nat Rev Genet 16:299–311

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Shoemaker RH (2006) The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 6:813–823

    Article  CAS  PubMed  Google Scholar 

  • Silva JM, Li MZ, Chang K, Ge W, Golding MC, Rickles RJ, Siolas D, Hu G, Paddison PJ, Schlabach MR, Sheth N, Bradshaw J, Burchard J, Kulkarni A, Cavet G, Sachidanandam R, Mccombie WR, Cleary MA, Elledge SJ, Hannon GJ (2005) Second-generation shRNA libraries covering the mouse and human genomes. Nat Genet 37:1281–1288

    CAS  PubMed  Google Scholar 

  • Singh S, Carpenter AE, Genovesio A (2014) Increasing the content of high-content screening: an overview. J Biomol Screen 19:640–650

    Article  PubMed  PubMed Central  Google Scholar 

  • Song M, Jeong E, Lee TK, Tsoy Y, Kwon YJ, Yoon S (2015) Analysis of image-based phenotypic parameters for high throughput gene perturbation assays. Comput Biol Chem 58:192–198

    Article  CAS  PubMed  Google Scholar 

  • Song M, Lee H, Nam MH, Jeong E, Kim S, Hong Y, Kim N, Yim HY, Yoo YJ, Kim JS, Kim JS, Cho YY, Mills GB, Kim WY, Yoon S (2017) Loss-of-function screens of druggable targetome against cancer stem-like cells. FASEB J 31:625–635

    Article  CAS  PubMed  Google Scholar 

  • Sundar R, Brown J, Ingles Russo A, Yap TA (2017) Targeting ATR in cancer medicine. Curr Probl Cancer. doi:10.1016/j.currproblcancer.2017.05.002

    PubMed  Google Scholar 

  • Thoma CR, Zimmermann M, Agarkova I, Kelm JM, Krek W (2014) 3D cell culture systems modeling tumor growth determinants in cancer target discovery. Adv Drug Deliv Rev 69:29–41

    Article  PubMed  Google Scholar 

  • Tomczak K, Czerwinska P, Wiznerowicz M (2015) The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol 19:A68–A77

    Google Scholar 

  • Vempati UD, Chung C, Mader C, Koleti A, Datar N, Vidovic D, Wrobel D, Erickson S, Muhlich JL, Berriz G, Benes CH, Subramanian A, Pillai A, Shamu CE, Schurer SC (2014) metadata standard and data exchange specifications to describe, model, and integrate complex and diverse high-throughput screening data from the Library of Integrated Network-based Cellular Signatures (LINCS). J Biomol Screen 19:803–816

    Article  PubMed  Google Scholar 

  • Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O’kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN, Cancer Genome Atlas Research N (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98–110

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wang T, Wei JJ, Sabatini DM, Lander ES (2014) Genetic screens in human cells using the CRISPR-Cas9 system. Science 343:80–84

    Article  CAS  PubMed  Google Scholar 

  • Yang W, Soares J, Greninger P, Edelman EJ, Lightfoot H, Forbes S, Bindal N, Beare D, Smith JA, Thompson IR, Ramaswamy S, Futreal PA, Haber DA, Stratton MR, Benes C, Mcdermott U, Garnett MJ (2013) Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res 41:D955–D961

    Article  CAS  PubMed  Google Scholar 

  • Zeng X, Tao L, Peng Z, Qin C, Chen S, He W, Tan Y, Xia Liu H, Yang SY, Chen Z, Jiang YY, Chen YZ (2017) HEROD: a human ethnic and regional specific omics database. Bioinformatics. doi:10.1093/bioinformatics/btx340

    Google Scholar 

  • Zheng W, Thorne N, Mckew JC (2013) Phenotypic screens as a renewed approach for drug discovery. Drug Discov Today 18:1067–1073

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This research was supported by grants from the National Research Foundation of Korea (NRF), including the Basic Science Research Program (NRF-2015R1D1A1A01057815 and NRF-2016R1D1A1B03935110) and the Science Research Center Program (NRF-2016R1A5A1011974), which is funded by the Korean government (MEST).

Author information

Author notes

  1. Euna Jeong and Sung Ung Moon have contributed equally to this work.

Authors and Affiliations

  1. Center for Advanced Bioinformatics & Systems Medicine, Sookmyung Women’s University, Hyochangwon-gil 52, Yongsan-gu, Seoul, 140-742, Republic of Korea

    Euna Jeong, Sung Ung Moon, Mee Song & Sukjoon Yoon

  2. Department of Biological Sciences, Sookmyung Women’s University, Hyochangwon-gil 52, Yongsan-gu, Seoul, 140-742, Republic of Korea

    Sukjoon Yoon

Authors
  1. Euna Jeong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sung Ung Moon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mee Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sukjoon Yoon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sukjoon Yoon.

Ethics declarations

Conflict of interest

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jeong, E., Moon, S.U., Song, M. et al. Transcriptome modeling and phenotypic assays for cancer precision medicine. Arch. Pharm. Res. 40, 906–914 (2017). https://doi.org/10.1007/s12272-017-0940-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12272-017-0940-z

Keywords

Search

Navigation